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α-MHC
β-MHCThemain objective of this studywas to create a postnatalmodel for cardiac hypertrophy (CH), in order to explain
the mechanisms that are present in childhood cardiac hypertrophy. Five days after implantation, intraperitoneal
(IP) isoproterenol (ISO)was injected for 7 days to pregnant femalemice. The fetuseswere obtained at 15, 17 and
19 dpc from both groups, also newborns (NB), neonates (7–15 days) and young adults (6 weeks of age). Histo-
pathological examswere done on the hearts. Immunohistochemistry andwestern blot demonstratedGATA4 and
PCNA protein expression, qPCR real time the mRNA of adrenergic receptors (α-AR and β-AR), alpha and beta
myosins (α-MHC,β-MHC) andGATA4. After the administration of ISO, therewas no change in the number of off-
springs. We observed signiﬁcant structural changes in the size of the offspring hearts. Morphometric analysis re-
vealed an increase in the size of the left ventricular wall and interventricular septum (IVS). Histopathological
analysis demonstrated loss of cellular compaction and presence of left ventricular small ﬁbrous foci after birth.
Adrenergic receptors might be responsible for changing a physiological into a pathological hypertrophy. How-
ever GATA4 seemed to be the determining factor in the pathology. A new animal model was established for
the study of pathologic CH in early postnatal stages.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pathologic cardiac hypertrophy (CH) is a process usually studied in
adults, where the differentiated post mitotic myocardium is capable of
responding to different adverse stimuli, genetic as well as environmen-
tal, increasing its size. Since this process can develop cardiac insufﬁcien-
cy and culminate in sudden death [1], it's diagnosis is considered a
marker of poor prognosis. However this disease is not exclusive of
adulthood. Approximately 95% of cases of CH are detected between
the ages of 15 and 25 years [2]. It is estimated that the frequency of
CH in the fetal stage is around 7% and probably higher. About 11% of
the fetuses die in uterus due to this disease [3]. Physiologic CH is a key
process for heart development during the fetal period, it increases
while proliferation decreases and then, it decreases after birth as matu-
rity is achieved [4]. However, what mechanisms turn a physiological
into a pathological cardiac hypertrophy during fetal or postnatal lifeón en Biología del Desarrollo y
Federico Gómez, Mexico, D.F.,
ras-Ramos).
land Ltd. This is an open access articlestill remains a question, probably due to the lack of experimental
in vivo models.
Among the most utilized adult in vivo experimental models to in-
duce hypertrophy is the use of ISO. It is a simple, easy to administer
and reproducible method with low mortality [5–7] compared with
other techniques of short duration,with high stress or those that require
surgical procedures such as coronary artery ligature or transverse aortic
constriction that imply a high risk of morbidity and mortality [6,8].
ISO is a synthetic catecholamine with the addition of two methyl
groups. It is structurally similar to adrenaline and is joined to β-
adrenergic receptors (β-AR), producing a superior effect of up to ten
times that of adrenaline itself [9,10]. Different studies in adult murine
models have demonstrated the ﬂexibility of ISO. A single subcutaneous
(SC) dose of ISO between 10 and 85mg/kg in adult rats causes myocar-
dial necrosis and ﬁbrosis [11–15]. Low doses of ISO (0.3 to 6 mg/kg)
during the 1st, 2nd and 3rd weeks induce necrosis in areas of the
myocardium [16–18]. In turn,moderate doses (35mg/kg) administered
SC for 3 days induced dilated cardiomyopathy. Chronic treatment
(100 mg/kg) N2 weeks in adult rats produces diastolic dysfunction
and causes decrease of fatty acids and glucose in the myocardium.
Changes similar to those were observed in rat hearts after myocardialunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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istration with osmotic mini-pumps is able to cause CH after 7 days;
however, 14 days after treatment and once the mini-pumps have been
removed, the pathology reverses itself [21]. On the other hand, concen-
trations N5 mg and up to 60 mg/kg/day for 7 days after IP administra-
tion, favors a pathological hypertrophic response, which affects the
left ventricle (LV) in the adult rat [22,23]. Hypertrophy produced by
ISO is very similar to CH in humans, determined by microarray analysis
of mRNA expression. Genes found in the ISOmodel have a higher corre-
lation than CH generated by active exercise in 8-week-old adult mice
[23]. Finally, there is only one study that evidences the use of ISO during
pregnancy. However, results are contradictory as the authors observed
that CH reverses itself a few weeks after birth [24]. These studies all
demonstrate that the mechanisms and time of ISO administration are
important to obtain the degree of myocardial damage desired.
ISO is a β-adrenergic stimulant and is able to cross the placental
barrier like epinephrine [25,26]. We hypothesized that prolonged IP
administration of ISO in pregnant female mice is a stimulus capable of
altering the myocyte physiology during fetal and neonatal stages, gen-
erating a pathologic CH with LV involvement, similar to experimental
pathological models of hypertrophy generated in adulthood. For this
reason our goal was to analyze the effect of IP administration of ISO in
pregnant female mice for 7 days after the 5th day of implantation. We
believe that themodel proposed in this study not only raises new ques-
tions about the mechanisms of the evolution of this pathology, but can
also be used to generate markers for early detection, as well as for eval-
uating the use of cell and/or regenerative therapy as treatment.2. Methods
2.1. Mouse model for postnatal pathologic cardiac hypertrophy
To produce postnatal cardiac hypertrophy (p-CH), female Mus
musculus Balb/C strain mice, previously paired with males of the same
strain, were utilized. Observation of the vaginal plug was regarded as
day 0 of gestation. From the ﬁfth day postcoitus (dpc) shortly after the
implantation of the embryo, pregnant female mice were injected IP
with ISO 50 μg/kg/day (Sigma Aldrich, St. Louis, MO) in phosphate-
buffered saline solution (PBS) for 7 days. The fetuses were obtained at
(age groups) 15, 17 and 19 dpc from both groups, also newborns
(NB), neonates (7–15 days) and young adults 6 weeks of age.
Another group was formed with pathologic CH mice induced in
adult stage (CH-ad). The hypertrophy was induced in 6 week old mice
injected IP with 50 mg/kg/day of ISO for 7 days. They were sacriﬁced
8 days after the end of ISO administration [27,28].
A control group (CTR) for each group, was injected with PBS during
the same time period as the experimental groups. All the animals were
bred in the laboratory animal sources of the Hospital Infantil de México
Federico Gómez, under the Mexican Ofﬁcial Norm NOM-062-ZOO-
1999. They were kept in of 12 hour light/dark cycles.2.2. Evaluation of the effects of ISO in pregnant female mice
To conﬁrm the effects of ISO in the offspring of treated pregnant fe-
male mice, the maternal weight was recorded from the ﬁrst day of ges-
tation until the time of sacriﬁce. The number of reabsorptions by litter
and the number of offsprings were recorded. After labor or cesarean de-
livery, maternal hearts were washed by perfusion with PBS and ﬁxed in
3.5% paraformaldehyde. In both groups ISO and PBS, dissections of the
heart chambers and transverse dissections were performed. Images
were analyzed with a stereoscopic microscope (Olympus, Tokyo,
Japan). Micrographs and measurements of the dissected hearts along
the free walls of both ventricles were done using ImageJ 1.46 software
(National Institutes of Health, Bethesda, MD).2.3. Cardiac hemodynamics
Echocardiography was carried out at 6 weeks to supervise the cardiac
hemodynamics with a VisualSonics (Toronto, Canada) Vevo 770
echocardiograph, with a linear transducer (30″) in B and M modes. M
mode was used to measure the LV ejection fraction (LVEF) in ﬁve
6 week mice for of each group. Each mouse was anesthetized with
inhaled isoﬂurane (2% for induction and 1.5% for maintenance) [29].
2.4. Morphometric analysis
After mice were sacriﬁced, ﬁve hearts were taken from each age
group, from both study groups and washed by perfusion with PBS,
stopped in diastole with KCl, and ﬁxed in paraformaldehyde. The ratio
of the heart weight with the body weight (HW/BW) was determined
using the body weight in g and the heart weight in mg [28].
Morphometric analysis of the heart was done with micrographs
taken on a clear ﬁeld with a stereoscopic microscope using ImageJ
1.46 software. The followingwere determined: a) thickness of each ven-
tricular wall and IVS; b) ventricular lumen; c) total surface of the heart,
and d) left and right ventricular cavities.
2.5. Histological analysis
Evaluation of myocardial ﬁbrosis and interstitial space index was
done. Dissected hearts were dehydrated with alcohol (30–100%),
made transparent with cedar oil and embedded in parafﬁn. Transverse
dissections were done to obtain 5-μ-thick sections. Histological cuts
were deparafﬁnized and rehydrated with alcohol until water. Nuclei
were stained with hematoxylin and eosin. Three hearts from each age
group were analyzed and micrographs were taken at 40× using an op-
tical microscope. Three sections of each heart were evaluated in the LV
and IVS. At each level, three ﬁelds were selected. The analysis was car-
ried out using UTHSCSA Image Tool v.3.0. The area of muscle tissue
was determined and the remainder was considered to be interstitial
space [7,30].
2.6. Indirect immunoﬂuorescence
To establish the expression levels of the GATA4 transcription factor
and cell proliferation, immunoﬂuorescence studies were done using
an anti-GATA4 antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
and proliferating cell nuclear antigen (PCNA, Dako, U.S.A.). Three hearts
were used from each age group. Each trial was carried out in triplicate.
Tissue slides were treated with citrate solution at a 15 lb/in2 pressure
for antigen release. Nonspeciﬁc activity was treated with protein
blocking solution (Biogenex, Fremont, CA). The primary antibody was
visualized with anti-mouse Zenon Alexa Fluor 488 (Life Technologies,
Grand Island, NY). After washing, nuclei were contrasted with Draq7
(Biostatus, Leicestershire, UK). Finally, Vectashield was used as mount-
ingmedia (Vector Laboratories, Burlingame, CA). Histopathological cuts
were observed in a confocal microscope (Zen 2009, Carl Zeiss, Dublin,
CA). Micrographs were captured at 40× and 15 ﬁelds were evaluated
for each region (LV and IVS). ImageJ 1.46 program was used for quanti-
ﬁcation. Percentage of expression was calculated.
2.7. Western blot
Hearts were treated with lysis solution T-PER (Pierce, Rockford, IL).
For total protein extraction, protein quantiﬁcation was done according
to the Bradford method (Bio-Rad, Hercules, CA). Each sample was
diluted in protein loading buffer (30 μg) and polyacrylamide gel electro-
phoresis (10%) was carried out. Proteins were transferred to a PVDF
membrane, previously treated with blocking solution (5% nonfat dry
milk powder in TBS) for 1 h to prevent nonspeciﬁcity. Anti-GATA4 pri-
mary antibody was incubated in blocking buffer for 12 h at 4 °C.
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temperature and detection was performed using a western blotting
luminol reagent (Santa Cruz Biotechnology, Santa Cruz, CA). GAPDH
protein (Santa Cruz Biotechnology, Santa Cruz, CA) was used to deter-
mine the levels of expression of each protein. Photographic ﬁlm was
used to develop the pictures. Experimental and standard bands were
scanned and analyzed using the ImageJ 1.46 software. Experimental
data were normalized.2.8. qPCR real time
Fresh hearts from each groupwere dissected into three parts (RV, LV
and IVS) after removal the atrium and large vessels. Total RNA of the LV
was isolated using Trizol reagent (Life Technologies). cDNAwas synthe-
sized using 1mg of total RNA. The reactionswere carried out for each of
the genes using an Mx30005Tm QPCR system with MxPro QPCR v.3.00
(Agilent Technologies, Santa Clara, CA) and SYBR Green (Life Technolo-
gies) as detection systems. The total volume usedwas 20 μl using 100 ng
of cDNA. Ampliﬁcation conditions were as follows: 10 min of denatur-
ation at 95 °C followed by 40 cycles at 95 °C for 30 s, 60 °C for 30 s
and 72 °C for 30 s. The ﬁnal elongation step consisted of 72 °C for
10 min. The primers are indicated in Supplemental Table 1. Negative
control was performed with a PCR reaction that contained water. Each
PCR reaction was done in triplicate.
The Livakmethod (also called ΔΔCt) was used for analyzing the rel-
ative quantiﬁcation. Ribosomal RNA 18S gene was used for normaliza-
tion and as a relative calibrator of the genetic expression for each of
the genes in the different regions of the CTR and CH-ad groups [31].2.9. Analysis of results
Data were expressed as mean ± SD. For comparing values between
the two groups, Student t test was used; p b 0.05 was considered statis-
tically signiﬁcant.3. Results
3.1. Effect of isoproterenol in pregnant female mice
It is worth noting that ISO did not cause structural changes in female
mice during gestation. Supplemental Fig. 1, micrograph showing simi-
larity of hearts of pregnant females treated and control. A four-
chamber cut was made parallel to the atrioventricular and transverse
groove, taking as reference the ventricular base, without ﬁnding obvi-
ous morphological differences (p N 0.05). In regard to body weight
and heart weight, we were not able to establish signiﬁcant differences
in the females from the two groups. The average offsprings and
reabsorptions obtained in pregnant female mice treated with ISO were
similar to the CTR group (Table 1).Table 1
Oligonucleotides used in this work (todos fueron diseñados para este trabajo, si no, hay
que ponerles otra columna con la cita).
Gene Primer
Sense Antisense
α-AR GGCACAGAAGATGCTGACAA CTGCCCCTTGGTGACATACT
β-AR GGCATTGAGTGGACCTTCAT TCGAGGCTTCTGGAAGTTGGT
α-MHC GGCACAGAAGATGCTGACAA CTGCCCCTTGGTGACATACT
β-MHC GGCATTGAGTGGACCTTCAT TCGAGGCTTCTGGAAGTTGGT
RNA 18S GAGGTGAAATTCTTGGACCGG TCTTGGCAAATGCTTTCGCT3.2. Heart analysis of the offsprings treated with isoproterenol during
pregnancy
Prolonged administration (7 days) of ISO during development of the
offspring, caused changes in their behavior; a sedentary behavior was
evident in the mice shortly after birth and at 6 weeks, unlike offsprings
of PBS treated mice, due to cardiac alterations (Supplementary videos).
These results were supported by monitoring cardiac hemodynamics
in 6 week mice treated with ISO and were associated with a
moderate increase in LV pressure compared with 6 week CTR mice
(6 weeks: p-CH = 119 ± 5 mm Hg vs. CTR = 92 ± 7 mm Hg, p b 0.05);
the latter similar to that determined in CH-ad (95 ± 8 mm Hg, Fig. 1).
An increase in the size of the thymus, lung and liver shortly after birth
but not in body weight, without ﬁnding differences in growth between
the p-CH and CTR groups is worth noting (Supplemental Fig. 2).
In turn, hearts from the p-CH group during the different stages of the
study were visibly larger than in the CTR group (Supplemental Fig. 3).
Therefore, in the p-CH group the signiﬁcant increase in the size of the
heart was notable (HW/BW) especially after birth (Supplemental
Table 2). It's worth noting that morphometric analysis of the offspring
hearts of mice treated with ISO during their pregnancy, revealed that
the thickness of the right ventricular wall in the fetus hardly changed in
relation to the CTR group (Fig. 2A, B). In regard to the IVS,we found signif-
icant differences only between the age groups of 15 days and 6 weeks
(15 days p-CH = 1.28 ± 0.06 vs. CTR = 1.01 ± 0.05; 6 weeks p-CH =
1.52 ± 0.04 vs. CTR = 1.16 ± 0.03, p b 0.05) (Fig. 2B). Meanwhile in the
LV of the p-CH group, a signiﬁcant increase in thickness was evident in
the fetus of 19 dpc up to offsprings of 6 weeks (19 dpc: p-CH = 0.78 ±
0.02 vs. CTR = 0.62 ± 0.04; NB: p-CH = 0.89 ± 0.05 vs. CTR = 0.59 ±
0.05; 7 days: p-CH = 0.92 ± 0.01 vs. CTR = 0.69 ± 0.01; 15 d: p-CH =
1.38 ± 0.06 vs. 1.01 ± 0.05; 6 weeks: p-CH = 2.29 ± 0.04 vs. CTR =
1.39 ± 0.05, p b 0.05) (Fig. 2C), In addition, a reduction of N50% in the
diameter of the ventricular lumen was evident in the LV of the
offspring treated with ISO during pregnancy (NB: p-CH = 4.34 ± 0.35 vs.
CTR = 8.46 ± 0.38; 7 d: p-CH = 4.99 ± 0.39 vs. CTR = 7.49 ± 0.53; 15 d:
p-CH = 3.013 ± 0.03 vs. CTR = 7.61 ± 0.38; 6 weeks: p-CH = 0.43 ±
0.005 vs. CTR = 8.079 ± 0.001, p b 0.05) (Fig. 2E).
With the aimof validatinghypertrophywe compared the6weekmice
treated with ISO with a model of induced hypertrophy during the adult
stage. Anatomically we observed little variation, ﬁrst we found that
the heart size in relation to body size in the p-CH 6weekmicewas signif-
icantly higher than in the CH-admice (6weeks: p-CH=0.009±0.0004 vs.
CH-ad= 0.008±0.0002, p b 0.05). Also signiﬁcant differenceswere found
in the thickness of the LV of the p-CH 6 week mice than the induced
hypertrophy in adult stage (6 weeks: p-CH = 2.29 ± 0.04 vs. CH-ad =
1.82 ± 0.09, p N 0.05), while it's cavity decreased more considerably in
comparison with the CH-ad (6 weeks: p-CH = 0.43 ± 0.005 vs. PCH-ad =
3.16 ± 0.08, p b 0.05) (Fig. 2C, D).3.3. Histopathological changes
In the offsprings treatedwith ISO, themost signiﬁcant changes of the
IVS as well as of the LV in fetal and neonatal stage were the loss of the
parallel alignment of the ﬁbers (myoﬁbrillar disorganization). In the
majority of themyocytes, the presence of enlarged nuclei and excessive
cytoplasmic vacuoleswas also evident, similar to reports of hypertrophy
in the adult stage, inducedwith ISO (Fig. 3). After the offspring birth, the
presence of someﬁbrotic foci was evident in the LV and IVS; however, in
the 6 week mice multiple ﬁbrotic lesions were located mainly towards
the ventricular lumen, characterized by accumulation of myoﬁbroblasts
with an excess of extracellular matrix secondary to myoﬁbrillar degen-
eration (Fig. 3). This histological evidencewas clearly reﬂected in the in-
crease of the interstitial space index (Table 2). In contrast, in CTR group
of the same ages, myoﬁbrillar structure was normal without collagen
accumulation.
Fig. 1. Ventricular hemodynamics. A) Echocardiographic M-mode tracings from 6week treatedmice during gestation and control same age compared to cardiac hypertrophic adult mice
(CH-ad). The 6 week mice showed a pronounced increase in left ventricular dimensions equal to the hypertrophy of stage adult. B) Left ventricular function estimated from fractional
shortening measured at the end of the study periods (6 weeks) was signiﬁcantly better as compared with 6 W CTR.
Fig. 2. Evolution of morphological changes in response to the administration of isoproterenol during gestation. A–C) Gradual increase of free wall thickness of the ventricular and
interventricluar septum. D–E) Lumen area. F) Volume. Right ventricle = ﬁne dots; interventricular septum = coarse dots; left ventricle = continuous line. Signiﬁcant differences
*p b 0.05 compared with control.
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Fig. 3. Isoproterenol treatment induces cardiac hypertrophy and ﬁbrosis. A) Hematoxylin–eosin staining of representative images of 6 week offspring mice treated during gestation with
isoproterenol or PBS vs hypertrophy induced in adult stage. Fibrosis (*) were evident in both models with more damage in those treated during pregnancy and in the left ventricle.
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In the LV of offspringmice treatedwith ISO, a greater loss of prolifer-
ation was observed during the fetal stage compared to the CTR group
(17 dpc: p-CH = 20.07% vs. CTR = 79.32%; 19 dpc: p-CH = 15.8% vs.
CTR = 87.7%; p b 0.05). During the neonatal period, we found that the
proliferative activity seemed to recover without reaching normal values
(NB: p-CH = 78.2% vs. CTR = 93.02%, 7 days p-CH = 5.7% vs. CTR = 55.8%;
15 days: p-CH = 21.9% vs. CTR = 36.8%; Fig. 4A).3.5. mRNA expression for adrenergic receptors
In the LV of offsprings treated with ISO we observed a considerable
increase in the expression of the α1-AR messenger in fetal stage (six
times more than adults) that decreased in NB; however, the level of ex-
pression recovered at 7 days (N11 times). In the following ages analyzed
(15 days and 6weeks), the expression obtainedwas greater than that of
CH-ad (Fig. 4B). With respect to the CTR group, long-term mRNA
expression was always lower compared to the pathologic CH-ad
group. Although in some fetal and neonatal stages the expressionTable 2
Comparison HW/BW of offspring of pregnant mice treated with isoproterenol.
15 dpc 17 dpc 19 dpc NB
ISO 0.017 ± 0.001
(1.7%)⁎
0.012 ± 0.0017
(1.2%)⁎
0.014 ± 0.0019
(1.4%)⁎
0.015 ± 0.0007
(1.4%)⁎
CTR 0.014 ± 0.001
(1.4%)
0.0101 ± 0.000
(1.01%)
0.012 ± 0.001
(1.4%)
0.014 ± 0.0014
(1.6%)
Cardiac hypertrophy was determined by the ratio of the heart weight (mg) to body weight (g)
formed using the Student's t test.
⁎ Indicates signiﬁcant differences between groups (P b 0.05).increased (1 to 1.9), but it did not surpass the expression observed in
the adult stage hypertrophy (Fig. 4B).
In terms of themRNAof β1-AR, only in three age groups of the six an-
alyzed, was there an expression greater than that of CH-ad group
(15 dpc: p-CH ≥ 1. 2 times more; 7 days: p-CH ≥ 3.5 times more and
6 weeks: p-CH ≥ 0.5 times more, p b 0.05). In the CTR, at 15 dpc the β1-
AR increased its expression double than that of the pathologic CH-ad.
In the rest of the age group analyzed, determined expression values of
β1-AR were lower than the hypertrophy in adult stage (Fig. 4C).3.6. GATA4 in the left ventricle
The total percentage of positive nuclei to GATA4 found in the LV of
offsprings treated with ISO was always greater than the percentage ob-
tained in the CTR group. However, signiﬁcant differences were found
between in the 19 dpc to 6 weeks (19 dpc: p-CH = 91.4% vs. CTR =
43.5%; NB: p-CH = 80.60% vs. CTR = 40.7%; 7 days: p-CH = 68.2 vs.
CTR = 45.5%, 15 days: p-CH = 70.06% vs. CTR = 35.5%; 6 weeks: p-CH =
91.1% vs. CTR = 27.8%). GATA4 decreased up to 50% in the CTR group
throughout the study. Also, a signiﬁcant differencewas evident between7 D 15 D 6 W-AD CH-AD
0.016 ± 0.0006
(1.6%)⁎
0.007 ± 0.0002
(0.6%)⁎
0.009 ± 0.0004
(0.9%)⁎
0.008 ± 0.0002
(0.8%)⁎
0.011 ± 0.0008
(1.1%)
0.003 ± 0.0001
(0.4%)
0.005 ± 0.0002
(0.62%)
. The values are the mean ± SME (n = 5 animals/age/group). All comparisons were per-
Fig. 4. A)Mitotic activity of the left ventricle. Percentage of nuclei positive for proliferating cell nuclear antigen (PCNA). B–C) Relative expression ofα- and β-aderenergic receptors in the
left ventricle. Expression was quantiﬁed by extracting the total RNA of LV of age groups that received isoproterenol during gestation; qPCR real-time was used and normalized to the ex-
pression with the cardiac hypertrophy induced adult stage and 18S RNA by the 2Δ Ct method.
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p b 0.05) (Fig. 5A and B). These data were supported by Western blot,
where a gradual increase was clearly observed in the GATA4 protein
in the LV of mice treated with ISO during the neonatal and adult stage
in comparison to the CTR group (Fig. 5C).
3.7. Analyses of α and β myosin in the LV
In all the ages analyzed from both groups, a decrease in α-MHC
messenger expression was evident, including the 6 week mice. Howev-
er α-MHC expression from offsprings treated with ISO was generally
greater than in the CTR group (Fig. 6A). In contrast, β-MHC expression
increased in all the analyzed age groups treated with ISO, despite the
fact that the relative expression determined in the p-CH 6 week group
was 0.3 times greater than in the CH-ad. An upregulate of β-MHC was
evident in offspring of female mice treated with ISO, but these expres-
sion increased as the age increases (p b 0.05) (Fig. 6B).
4. Discussion
Cardiac hypertrophy can be of genetic or multifactorial etiology,
such as metabolic diseases [32]. The disease's natural history varies,
which makes its diagnosis difﬁcult, especially in children [33]. In the
majority of patients it can remain asymptomatic for a long period or
in a compensatory stage and later on, start slowly degenerating beforesuffering sudden death [34]. Nonetheless, its mechanisms have not
been studied much [35] during intra uterine life. In addition, the lack
of in vivo experimental models has led to the use of in vitro models
from primary rat or mice myocyte cultures in the neonatal stage along
with its limitations [36,37].
Using IP ISO during gestation for 7 days in pregnant female mice, we
managed to induce cardiac hypertrophy in the offspring. Our study
shows for the ﬁrst time some of the key molecular mechanisms that af-
fect the balance of physiological hypertrophy during fetal and neonatal
stages, and that can contribute to pathological hypertrophy. It is impor-
tant to state that progressive hypertrophy, non-reversible in the off-
spring treated with ISO during gestation, was not caused by maternal
alterations, neither did the offspring pathology alter the physiology of
the pregnant femalemice. This eventwill raise newquestions onmater-
nal–fetal relationships. Results were contrary to the pioneer study
published by Iwasaki [24], where the use of ISO during gestation, ad-
ministered SC for 5 days in pregnant female rats causes a moderate
growth of the LV in the hearts of the offspring, out of proportion to
the IVS and intra- and intercellular disarrangement 4 weeks after
birth. The physiology is progressively reverted as the age group the off-
spring increases.
It should be noted that the signiﬁcant increase in the heart weight/
bodyweight ratio andmorphometricmeasurements, where an increase
in ventricularwall thickness and reduction in the ventricular lumenwas
observed, are coherent with the anatomical changes described in
Fig. 5.Analysis of GATA4 protein expression. A) Percentage of nuclei positive to GATA4 protein in the left ventricle. Comparison between treated subject and control, signiﬁcant at p b 0.05
(*); and comparison between hypertrophy 6weekmice vs hypertrophy adult stage, signiﬁcant at p b 0.001 (**), B) Immunoﬂuorescence against GATA-4 (green). Representative images of
6 week mice offspring treated with ISO during gestation or PBS vs hypertrophy induced adult stage. DraQ7-stained nuclei (blue). C) Determination of Gata-4 protein for Western blot.
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[27,38]. These results do not correspond to what some authors suggest
in regard to the disproportionate thickening of the septum, which is a
common effect in human hearts during development, and is then lost
during pre- and postnatal growth [39].
Histologicallywe found three basic processes that have repercussion
in the heart after IP administration of ISO during gestation, wheninducing postnatal hypertrophy. The ﬁrst process was the loss of cell
proliferation, followed by the loss of cell compaction and ﬁbrotic foci.
In regard to the proliferation during the fetal stage, we attribute that
the loss of proliferation was due to the negative effect that the ISO ago-
nist has over the β-adrenergic receptors, as suggested by in vitro culture
studies [40]. We assume that the presence of ISO during the embryonic
stage, allows a fraction of β-adrenergic receptors coupled to G proteins,
Fig. 6. Relative expression of α-MHC and β-MHC in the left ventricle. Expression was quantiﬁed by extracting the total RNA of LV of fetuses, neonatal and 6 weeks that received isopro-
terenol during gestation. qPCR real-time was used and normalized to the expression of the cardiac hypertrophy induced in adult stage and 18S RNA by the 2Δ Ct method.
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would allow the activation of non-classical routes that participate in
cell proliferation, apoptosis and cell growth processes: activation of
phosphodiesterase 4 (PDE4), that blocks cyclic AMP production [41];
activation of the PI3K route (phosphatidyl-inositol 3-kinase), or expres-
sion of transcription factor NF-κB (kappa beta nuclear factor) and the
activation of Akt/PKB [42]; or expression of proinﬂammatory cytokines
(IL-1 β, IL-6, IL-18 e IL-13) [43], or increase of vascular endothelial
growth factor (VEGF); or cardiac remodeling proteins that increase
the collagenase activity (collagen, ﬁbronectin and metalloproteinases
of the extracellular matrix [MMP]); or also signaling route activation
of Ras/Raf/MEK/ERK (kinases regulated by extracellular signals) and
MAPK (kinase proteins activated by mitogens) [44], not yet explored
in this study. On the other hand the possibility exists that the negative
effect of ISO over the β-adrenergic receptors in the embryonic stage,
allows the expression ofα-adrenergic receptors, which could modulate
the progression of the disease. Since the results of qPCR real time
showed that mRNA α-adrenergic receptors are the most abundant
during the progression of the disease, the results seen in this study are
congruent with the cardiac pathologies described in transgenic mice
when there is overexpression of some of the subtypes of α1-AR
[45–48]. Therefore, we believe that the analysis of receptor expressions
in intrauterine life could be the ﬁrst step in determining heart failure.
In our study we demonstrated that IP administration of ISO also af-
fects cell compaction after birth. Even though we did not analyze the
changes in the expression of cell adhesion proteins like camp, or of
the extracellular matrix, like collagen or ﬁbronectin, the increase of in-
terstitial space shows damage to the LV, possibly due to the loss of cell
junction. Even without evaluating cell death in the different ages of
the study, it was possible to localize some ﬁbrotic foci in the LV of
mice treated with ISO during gestation, from day 7 up to 6 weeks.
These data support the results observed in ﬁbroblast cultures where
ISO is able to regulate the myoﬁbroblast function responsible for colla-
gen synthesis [49]. We propose that the observed ventricular growth
was due to the increase in size of the myocytes and not to proliferation.
In the futurewe are considering the evaluation of collagen types l and III,
since studies by Marijianoski et al. suggest that the exchange of type III
collagen for type I is essential for normal heart development. Duringfetal and neonatal stages the greater portion of collagen is type III
(favoring elasticity) which, little by little, is substituted by type I colla-
gen, responsible for providing rigidity to the microenvironment of the
myocyte [50].
During hypertrophy in the adult stage the reinduction of embryo-
fetal stage genes is suggested, among which we can highlight GATA4
to be one of the predominant markers. Its expression is dependent on
AR activation and PKAor PKC signalingmechanisms [21]. For this reason
we decided to evaluate the changes in the expression of the protein of
GATA4. It should be highlighted that in this study we evidenced that
the percentage of nuclei positive to GATA4 is not reduced in the LV or
in the IVS when mice are treated with ISO during gestation, compared
with CTR. These results are in accordance with the protein increase ob-
served in Western blot. They suggest that GATA4 plays an important
role in the evolution of the disease postnatally. Note that GATA4 could
be considered amarker of poor prognosis, itwould be appropriate to de-
termine it in theﬁrstweek of life, especially in caseswhere echocardiog-
raphy revealed an impaired LV.
Changes in the expression proﬁle of α-MHC and β-MHC are indica-
tive of structural changes in the sarcomere. In our study they were key
elements in determining the effect of ISO on gestation. Sadoshima and
Izumo documented that the substitution of α-MHC for β-MHC expres-
sion is a typical event in CH in the adult heart [51].Waspe et al. reported
that β-MHC is highly expressed in murinemodels during the fetal stage
and decreases suddenly after birth, whereas α-MHC represents 40% in
the ﬁrst week of life and only 5%, 3 weeks later [52]. In this regard, our
results demonstrate that mRNA expression of β-MHC in the LV does
not change when offspring are treated with ISO during gestation, al-
though after birth a reduction in the expression of the isoform was evi-
dent. We clearly observed that the expression of theα-MHCmessenger
increases in mice treated with ISO during gestation as the pathology
progresses. α-MHC expression was possibly regulated by the expres-
sion of the GATA-4 transcription factor, as various studies have demon-
strated that the GATA box (59-AGATAA-39) is present in the promoter
regions of α-MHC [53] and cardiac troponin C [54].
We believe that this model will allow us to conﬁrm the proposed
in vitro regulation mechanisms, using primary cultures of myocytes
from the neonatal stage. It will also be useful in the design of alternative
139A. Del Olmo-Turrubiarte et al. / IJC Heart & Vasculature 7 (2015) 131–140therapies that encourage regeneration or prevent cell damage. It also
raises new questions about the activationmechanisms of adrenergic re-
ceptors and/or how themechanisms are regulated once the stimuli have
activated the pathways. Among the possible candidates, we mention
angiotensin II [55] or neuregulin [56–58]. Both are associated with
neuro-humoral stimuli including changes of electric ﬂow dependent
on the membrane potential that at this time are not yet determined.
Furthermore, it could be that these systems are regulated by reactive
oxygen species capable of regulating the AR, as has been shown in cul-
tured myocytes in adult and neonatal mice [59].
5. Conclusion
With the IP administration of ISO in this study, we demonstrate for
the ﬁrst time in an in vivo model, some molecular mechanisms that
are altered in heart development. Adrenergic receptors might be re-
sponsible for directing a physiological into a pathological hypertrophy.
However GATA4 seemed to be the determining factor in the pathology.
Thismodel can be used for early detection of biomarkers or to create re-
generative therapies to reestablish the cardiac structure, avoiding ische-
mia and therefore, sudden death in the pediatric age.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcha.2015.02.005.
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